|May 02, 2019||CTI BioPharma Reports First Quarter 2019 Financial Results|
|SEATTLE, May 2, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2019.
"Advancing our U.S. and European development program for pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia remains our top priority for 2019, and we anticipate multiple important milestone events for pacritinib this year," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. ... |
|Apr 03, 2019||CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10|
|SEATTLE, April 3, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central.
18th Annual Needham Healthcare Conference
Wednesday, Apr. 10
|Mar 13, 2019||CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights|
|SEATTLE, March 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2018.
"The Company is focused on advancing its development program of pacritinib for the treatment for myelofibrosis patients with severe thrombocytopenia in the United States and Europe in 2019," commented Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. "Following the previously-announced completi... |